Caroline G. Ploeger

Mrs. Caroline G. Ploeger

University of Louisville School of Medicine, Louisville, Kentucky, USA
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2025 in Orbit
Verified
Journal Article
Closed access
TGTanya Gupta
Tanya Gupta
Caroline G. PloegerCaroline G. Ploeger
Caroline G. Ploeger
MKMohsen B. Kashkouli
Mohsen B. Kashkouli
EHEyas M. Hattab
Eyas M. Hattab
JCJeremy D. Clark
Jeremy D. Clark
To present three new cases of primary intraosseous orbital hemangioma (PIOH), including rare lacrimal bone involvement, and to provide an updated systematic review of previously reported cases. We retrospectively reviewed three patients with orbital PIOH from our institution. Clinical, radiographic, histopathologic, and surgical findings were analyzed. A comprehensive systematic review of 84 previously published PIOH cases was performed to assess demographics, anatomic location, imaging, and treatment outcomes. All three patients had firm, progressively enlarging orbital masses. Imaging showed well-circumscribed, expansile lesions confirmed as PIOH histologically. Case 1 involved the zygomatic and sphenoid bones; Case 2, the maxilla and lacrimal bone; and Case 3, the frontal bone. All underwent orbitotomy with subtotal or complete excision and reconstruction. No recurrence was observed at 1-34 month follow-up. In the systematic review, the zygoma (50%) and frontal bone (44%) were most frequently involved. Common symptoms included swelling, proptosis, pain, and globe displacement. CT was the most used imaging modality. Surgical excision, often with preoperative embolization, remains the preferred treatment. Only one recurrence (1.8%) was reported out of the 56 cases with follow-up data. Orbital PIOH is a rare vascular tumor best managed by tailored surgical excision. Our findings and updated systematic review emphasize individualized planning, particularly in rare sites like the lacrimal bone.

19 May 2025 in Reproductive Medicine
Verified
Journal Article
Open access
PDF file
Caroline G. PloegerCaroline G. Ploeger
Caroline G. Ploeger
KHKate Hansen
Kate Hansen
ABAmmon Bayles
Ammon Bayles
ABAdriana Burger
Adriana Burger
JHJason Hansen
Jason Hansen
TJTimothy G Jenkins
Timothy G Jenkins
Background/Objectives: In the past 50 years, human reproductive capacity has steadily declined with elusive and idiopathic origins. Amongst theorized causes, oxidative stress has been proposed to directly contribute to male infertility. The glutathione (GSH) and glutathione disulfide (GSSG) molecular couple reflect cellular redox environments and are thus reflective of oxidative stress in most cells. Shifting GSH/GSSG redox states to abnormal, more oxidizing conditions can disrupt normal cellular activities. This study explores the correlation between the GSH/GSSG redox system and factors involved in male infertility, including sperm quality, specifically sperm motility and total count. Methods: Semen samples from 98 patients underwent high-performance liquid chromatography (HPLC) for GSH/GSSG analysis. A protein assay determined the protein concentration for normalization, and GSH/GSSG redox potentials (Eh) were calculated using the Nernst equation. Results: A significant inverse correlation between GSH/GSSG Eh and sperm count was identified (p = 0.0046 and R2 = 0.071). Analysis also found that cellular GSH concentrations (p < 0.001 and R2 = 0.11) and total GSH (GSH + (GSSG × 2); p = 0.0039 and R2 = 0.074) were significantly and positively correlated with total sperm count, whereas GSSG concentrations were not. The correlation between redox potential and motility was not significantly different (p = 0.11 and R2 = 0.02). Conclusions: This study shows that total sperm count decreases with increasing redox potential, indicating that more oxidized systems, such as the GSH/GSSG system, are associated with lower sperm counts in ejaculated sperm samples. These findings support a potential link between oxidative stress and sperm parameters. As understanding of the relationship between GSH/GSSG Eh and sperm quality improves, this may inform future potential therapies and approaches aimed at supporting male reproductive health.

1 March 2026 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
Caroline G. PloegerCaroline G. Ploeger
Caroline G. Ploeger
CVCarolina Carvalho Soares Valentim
Carolina Carvalho Soares Valentim
MGMehmet Eren Guner
Mehmet Eren Guner
MGMelis Kabaalioglu Guner
Melis Kabaalioglu Guner
Purpose: To review and compare the efficacy and safety of adult and pediatric biologic biosimilar use for the treatment of noninfectious uveitis (NIU). Methods: A review of the literature from inception to December 2025 was conducted using Pubmed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to identify studies that included data or discussion on the use of biosimilar biologic agents for adult and/or pediatric NIU. Articles related to these topics were included and discussed within this review. Results: Most studies examining biosimilar use in adult and pediatric noninfectious uveitis have evaluated the efficacy and safety of anti-tumor necrosis factor alpha (anti-TNF-α) agents, primarily adalimumab and infliximab biosimilars. Identified studies in both adults and children largely consisted of two designs: those comparing reference biologics with biosimilars and switch studies assessing outcomes following conversion to biosimilar therapy. Golimumab, certolizumab pegol, tocilizumab, sarilumab, and rituximab reference biologic studies offer promising results for treatment of NIU, but clinical trials evaluating biosimilar biologics lack in the literature. Compared with adult populations, pediatric cohorts treated with biosimilars for NIU are underrepresented in the literature. Conclusion: Current evidence suggests that adalimumab and infliximab biosimilars are effective and safe in comparison to reference biologics for treatment of NIU in the adult and pediatric populations. Expanded investigation in pediatric cohorts, including prospective clinical trials and inclusion of other biosimilar biologic agents are needed to address current gaps in evidence and to inform clinical decision-making.

1 November 2025 in Journal of Pediatric Ophthalmology & Strabismus
Verified
Journal Article
Closed access
Caroline G. PloegerCaroline G. Ploeger
Caroline G. Ploeger
CVCarolina Carvalho Soares Valentim
Carolina Carvalho Soares Valentim
MGMehmet Eren Guner
Mehmet Eren Guner
Giant-cell tumors of bone (GCTBs) are benign, expansile lesions usually found in the long bones of young adults. The authors report a pediatric skull base GCTB causing cranial nerve deficits and vision loss. The patient presented with blurry vision, left eye misalignment, headaches, nausea, and vomiting. Imaging revealed a large heterogenous mass invading the anterior cranial fossa floor. Initial histopathology suggested an aneurysmal bone cyst (ABC), and the mass was surgically resected. Four months later, recurrence led to genetic testing, which identified a p.G35W H3F3A mutation, confirming GCTB with secondary ABC of the pituitary fossa causing right compressive optic neuropathy and left orbital apex syndrome. Management included repeat resection and denosumab therapy, achieving radiographic stability with preservation of vision in the right eye, although the optic nerve of the left eye remained atrophic. Given the diagnostic overlap between GCTB and ABC, the authors emphasize the importance of genetic testing for accurate and early diagnosis to enable timely treatment and reduce the risk of recurrence.

26 February 2026 in medtigo Journal of Medicine
Verified
Journal Article
Open access
GNGeorge Nemeth
George Nemeth
Caroline G. PloegerCaroline G. Ploeger
Caroline G. Ploeger
TGTanya Gupta
Tanya Gupta
SLShelby Lands
Shelby Lands
CWCole Wyatt
Cole Wyatt
SDShorye Durrett
Shorye Durrett